Quantcast
Home > Quotes > VCNX
VCNX

Vaccinex, Inc. Common Stock (VCNX) Quote & Summary Data

$4.97
*  
0.051
1.04%
Get VCNX Alerts
*Delayed - data as of Mar. 25, 2019  -  Find a broker to begin trading VCNX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 4.01 / $ 5.05
Today's High / Low
$ 5.08 / $ 4.75
Share Volume
7,913
50 Day Avg. Daily Volume
8,389
Previous Close
$ 4.919
52 Week High / Low
$ 12 / $ 3.32
Market Cap
57,034,473
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
7,913
50 Day Avg. Daily Volume:
8,389

Trading Range

The current last sale of $4.97 is 49.70% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.08 $ 12
 Low: $ 4.75 $ 3.32

Company Description (as filed with the SEC)

We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. We believe we are the leader in the field of SEMA4D biology and that we are the only company targeting SEMA4D as a potential treatment for cancer, neurodegenerative diseases, or autoimmune disorders. SEMA4D is an extracellular signaling molecule that regulates the migration of immune and inflammatory cells to sites of injury, cancer or infection. We are leveraging our SEMA4D antibody platform and our extensive knowledge of SEMA4D biology to develop our lead product candidate, VX15, which we believe utilizes novel mechanisms of action. In June 2018, the U.S. Adopted Name Council approved the use of pepinemab as the adopted name for VX15.  ... More ...  



Risk Grade

Where does VCNX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 5.08
Open Date:
Mar. 25, 2019
Close Price:
$ 4.97
Close Date:
Mar. 25, 2019


Consensus Recommendation

Analyst Info